Subdivision of M1 Stage for De Novo Metastatic Breast Cancer to Better Predict Prognosis and Response to Primary Tumor Surgery

Abstract

Background: Patients with de novo metastatic breast cancer (MBC) constitute a heterogeneous group with different clinicopathologic characteristics and survival outcomes. Despite controversy regarding its prognostic value, primary tumor surgery may improve survival for selected patients. Patients and Methods: Patients with de novo MBC were identified using the SEER database and were then divided randomly into training and validation sets. A Fine-Gray competing risks model was developed to identify the variables associated with increased cancer-specific mortality in the training set. The M1 subdivision system was established based on the independent prognostic factors. Cumulative incidence curves were estimated and compared using Gray’s test. Results: Involvement of brain or liver and number of metastatic sites were identified as independent prognostic factors in multivariate analysis. The M1 category was subdivided into 3 subcategories: M1a, single site involvement except brain and liver; M1b, liver involvement only, or multiple site involvement except brain and liver; and M1c, brain involvement regardless of number of metastatic sites, or liver and other sites involvement except brain (M1b vs M1a: subdistribution hazard ratio [SHR], 1.48; 95% CI, 1.29–1.68; M1c vs M1a: SHR, 2.45; 95% CI, 2.18–2.75). Patients with the M1a subtype benefited most from primary tumor surgery in the adjusted competing risks model (M1a: SHR, 0.57; 95% CI, 0.48–0.67, M1b: SHR, 0.62; 95% CI, 0.47–0.83, and M1c: SHR, 0.59; 95% CI, 0.44–0.80), whereas benefits conferred by treatment with chemotherapy alone increased with the upstaging of metastatic disease (M1a: SHR, 0.72; 95% CI, 0.62–0.83, M1b: SHR, 0.54; 95% CI, 0.44–0.68, and M1c: SHR, 0.53; 95% CI, 0.45–0.61). Conclusions: Subdivision of M1 stage facilitates prognosis prediction and treatment planning for patients with de novo MBC. Treatment offered should be decided in a coordinated multidisciplinary setting. Primary tumor surgery may play an important role in the management of selected patients.

Breast Cancer-Specific Mortality in Small-Sized Tumor with Stage IV Breast Cancer: A Population-Based Study

“…In our study, age over 65 was found to be an independent predictor of worse BCSM (HR, 1.671; p < .0001). Moreover, our study consolidates the notion [21, 22] that involvement of brain or liver is an independent prognostic factor for stage IV breast cancer. In multivariate analysis, brain or liver metastasis indicated worse BCSM (HR, 2.115, 1.574; p < .0001, p = .002, respectively).…”

Breast Subtypes and Prognosis of Breast Cancer Patients With Initial Bone Metastasis: A Population-Based Study

“…The current study indicated that apart from patients with bone and brain metastasis, patients of other metastatic patterns might benefit from surgery. Likewise in a subdivision analysis of M1 patients, preferred prognosis was seen across all subdivisions after surgery except M1c category which is defined as brain involvement or multiple visceral metastasis ( 42 ). When it comes to molecular subtype, previous studies showed less benefit of surgery in metastatic triple-negative breast cancer (TNBC) patients.…”

Role of Locoregional Treatment in De Novo Stage IV Breast Cancer

“…Therefore, the study suggests that LRT may benefit a select group of patients with indolent disease. Going along with the goal to specify which subset of stage IV disease would benefit the most from LRT, Lin et al 13 in 2019 describes the idea of subdivision of M1 stage to better predict prognosis and response to LRT. It is well-known that patients with de novo stage IV BC express heterogeneity with different clinicopathologic and prognostic factors.…”